• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chamath Palihapitiya's SPAC Nearly Doubles Following Business Combo With Video Game Therapeutics Company

    8/20/22 4:07:05 PM ET
    $DNAA
    Get the next $DNAA alert in real time by email

    Special purpose acquisition company Social Capital Suvretta Holdings Corp. I (NASDAQ:DNAA), sponsored by U.S.-Canadian venture capitalist Chamath Palihapitiya, jumped nearly 200% in after-hours trading on Friday.

    What Happened: DNAA’s after-hours surge came on top of the nearly 50% gain the stock clocked during regular trading.

    The gains look even more palatable when weighed against Friday’s broader market plunge.

    In an after-hours release, digital medicine company Akili said it has completed its previously announced business combination with Palihapitiya’s Social Capital Suvretta Holdings Corp. I. The combined company, to be known as Akili, will begin trading on the Nasdaq on Aug. 22.

    Akili is a healthcare company engaged in the development of cognitive treatments, leveraging technologies designed to directly target the brain.

    Akili raised more than $183 million in gross proceeds from the transaction. It expects to use the proceeds to fund the commercial launch of EndeavorRx, a Food and Drug Administration-cleared and CE mark certified prescription video game for pediatric attention deficit hyperactivity disorder patients. The company expects to commercialize it in the fourth quarter.

    The company also has late-stage product candidates for treating neuropsychiatric diseases, including autism spectrum disorder, multiple sclerosis, and major depressive disorder.

    See also: S&P 500 Snaps 4-Week Winning Streak As Investors Anticipate Higher Interest Rates

    Why It’s Important: Taking to Twitter, Palihapitiya said he is investing $100 million in Akili to “address the growing and worsening mental health crisis” in the U.S.

    Palihapitiya, popularly known as the SPAC king, has seen his net worth shrink after the SPAC phenomenon lost its appeal. SPACs make up the bulk of his portfolio. Many of his portfolio companies that went public this year are trading at sub-$10 levels.

    DNAA has also been trading around the level since it was listed in mid-2021.

    DNAA closed Friday’s session 48.26% higher at $14.07 and added an additional 198.51% to $42 in the after-hours session, according to Benzinga Pro data.

    Photo: Courtesy of TechCrunch on flickr

    Get the next $DNAA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PureTech Health plc – Half-Year Report

    Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

    8/25/22 2:07:00 AM ET
    $CPSR
    $DNAA
    $GLS
    Business Services
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

    Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol "AKLI" on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (NASDAQ:DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. ("Akili"), is expected to start trading on The Nasdaq Capital Market ("Nasdaq") under the new ticker symbol "AKLI" on August 22, 2022. Akili raised more than $163 million from the

    8/19/22 5:25:00 PM ET
    $DNAA

    PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

    New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta H

    7/11/22 7:05:00 AM ET
    $DNAA
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jina Anil (Amendment)

    3/A - Akili, Inc. (0001850266) (Issuer)

    12/13/22 8:14:59 PM ET
    $DNAA

    SEC Form 3 filed by new insider Ehlert Kenneth (Amendment)

    3/A - Akili, Inc. (0001850266) (Issuer)

    12/13/22 8:15:13 PM ET
    $DNAA

    SEC Form 3 filed by new insider Martucci Walter Edward Ii (Amendment)

    3/A - Akili, Inc. (0001850266) (Issuer)

    12/13/22 8:10:52 PM ET
    $DNAA

    $DNAA
    SEC Filings

    View All

    SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

    424B3 - Akili, Inc. (0001850266) (Filer)

    1/12/23 8:13:45 AM ET
    $DNAA

    Social Capital Suvretta Holdings Corp. I filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Akili, Inc. (0001850266) (Filer)

    1/12/23 8:06:32 AM ET
    $DNAA

    SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

    424B3 - Akili, Inc. (0001850266) (Filer)

    1/5/23 7:21:42 AM ET
    $DNAA

    $DNAA
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer

    Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where

    3/17/22 9:05:00 AM ET
    $DNAA
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer

    Jon David brings deep expertise in building and launching engaging products to the Akili leadership team Akili Interactive ("Akili" or the "Company"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where the treatment is experienced like high-end entertainment. Reporting to the CEO, David will join the Akili executive team, which includes leader

    3/17/22 9:00:00 AM ET
    $DNAA

    $DNAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

    SC 13G - Akili, Inc. (0001850266) (Subject)

    1/20/23 6:27:44 AM ET
    $DNAA

    SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. I

    SC 13D - Akili, Inc. (0001850266) (Subject)

    8/30/22 4:48:09 PM ET
    $DNAA

    SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

    SC 13G - Akili, Inc. (0001850266) (Subject)

    8/29/22 12:28:20 PM ET
    $DNAA

    $DNAA
    Financials

    Live finance-specific insights

    View All

    PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

    In addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:KRTX), Vor Biopharma (NASDAQ:VOR) and Gelesis (NYSE:GLS) Fully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management's Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures Transaction values the combined co

    1/26/22 7:02:00 AM ET
    $DNAA
    $GLS
    $KRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

    Akili's leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases, including expanded ADHD populations, multiple sclerosis, autism, and depression Transaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in

    1/26/22 7:00:00 AM ET
    $DNAA